EP3893919A4 - Pegylated growth hormone antagonists - Google Patents

Pegylated growth hormone antagonists Download PDF

Info

Publication number
EP3893919A4
EP3893919A4 EP19896879.4A EP19896879A EP3893919A4 EP 3893919 A4 EP3893919 A4 EP 3893919A4 EP 19896879 A EP19896879 A EP 19896879A EP 3893919 A4 EP3893919 A4 EP 3893919A4
Authority
EP
European Patent Office
Prior art keywords
growth hormone
hormone antagonists
pegylated growth
pegylated
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19896879.4A
Other languages
German (de)
French (fr)
Other versions
EP3893919A1 (en
Inventor
Richard S. Brody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Technologies Laboratories LLC
Original Assignee
Molecular Technologies Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/216,230 external-priority patent/US10874717B2/en
Application filed by Molecular Technologies Laboratories LLC filed Critical Molecular Technologies Laboratories LLC
Publication of EP3893919A1 publication Critical patent/EP3893919A1/en
Publication of EP3893919A4 publication Critical patent/EP3893919A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19896879.4A 2018-12-11 2019-12-10 Pegylated growth hormone antagonists Pending EP3893919A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/216,230 US10874717B2 (en) 2015-07-07 2018-12-11 Pegylated growth hormone antagonists
PCT/US2019/065385 WO2020123450A1 (en) 2018-12-11 2019-12-10 Pegylated growth hormone antagonists

Publications (2)

Publication Number Publication Date
EP3893919A1 EP3893919A1 (en) 2021-10-20
EP3893919A4 true EP3893919A4 (en) 2022-11-30

Family

ID=71076634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19896879.4A Pending EP3893919A4 (en) 2018-12-11 2019-12-10 Pegylated growth hormone antagonists

Country Status (4)

Country Link
EP (1) EP3893919A4 (en)
JP (1) JP2022511951A (en)
CA (1) CA3121241A1 (en)
WO (1) WO2020123450A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170007711A1 (en) * 2015-07-07 2017-01-12 Richard S. Brody Pegylated growth hormone antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
JP2008525473A (en) * 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Modified human growth hormone
US10874717B2 (en) 2015-07-07 2020-12-29 Burr Oak Therapeutics LLC Pegylated growth hormone antagonists
WO2019211842A1 (en) 2018-04-30 2019-11-07 Opko Biologics Ltd. Long-acting human growth hormone-antagonists and methods of producing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170007711A1 (en) * 2015-07-07 2017-01-12 Richard S. Brody Pegylated growth hormone antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 9 March 2017 (2017-03-09), "Human mutant growth hormone (GH) protein (G120K/H151C), SEQ ID 18.", XP055943327, retrieved from EBI accession no. GSP:BDN14369 Database accession no. BDN14369 *
DATABASE Geneseq [online] 9 March 2017 (2017-03-09), "Human mutant growth hormone (GH) protein (G120K/N99C), SEQ ID 14.", XP055944163, retrieved from EBI accession no. GSP:BDN14365 Database accession no. BDN14365 *
See also references of WO2020123450A1 *

Also Published As

Publication number Publication date
WO2020123450A1 (en) 2020-06-18
JP2022511951A (en) 2022-02-01
CA3121241A1 (en) 2020-06-18
EP3893919A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
EP3814381A4 (en) Trispecific antagonists
EP3833683A4 (en) Polypeptide integrin antagonists
EP3801694A4 (en) Auto-insert injector
EP3750579A4 (en) Injector
GB201905552D0 (en) Antagonists
EP3826702A4 (en) Injector
EP3920961A4 (en) Growth hormone-releasing hormone antagonists and uses thereof
EP3650460A4 (en) Polypeptide pharmaceutically acceptable salt et use thereof
EP3858868A4 (en) Polypeptide composition
EP3873918A4 (en) Insecticidal proteins
EP3802565A4 (en) Polypeptides
EP4044792C0 (en) Harvester
EP4034570A4 (en) Heterodimeric proteins
EP3978510A4 (en) Norovirus-binding peptide
EP3897104A4 (en) Insecticidal proteins
EP3851448A4 (en) Anti-erythropoietin receptor peptide
EP3904039A4 (en) Injector
EP3874069A4 (en) Insecticidal proteins
EP3840572A4 (en) Selectively-accessible feeder
AU2019350356A1 (en) Arginase1 polypeptides
EP3765623A4 (en) Insecticidal proteins
EP3983002A4 (en) Therapeutic pegylated growth hormone antagonists
EP3817538A4 (en) Feeder
EP3893919A4 (en) Pegylated growth hormone antagonists
EP4069702A4 (en) Sstr5 antagonists

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/61 20060101ALI20220725BHEP

Ipc: A61K 47/60 20170101ALI20220725BHEP

Ipc: A61K 38/27 20060101AFI20220725BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20221031

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/61 20060101ALI20221025BHEP

Ipc: A61K 47/60 20170101ALI20221025BHEP

Ipc: A61K 38/27 20060101AFI20221025BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240301